|
1
|
Barbui T, Thiele J, Vannucchi AM and
Tefferi A: Rationale for revision and proposed changes of the WHO
diagnostic criteria for polycythemia vera, essential
thrombocythemia and primary myelofibrosis. Blood Cancer J.
5:e3372015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haider M, Gangat N, Lasho T, Hussein AK
Abou, Elala YC, Hanson C and Tefferi A: Validation of the revised
international prognostic score of thrombosis for essential
thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am
J Hematol. 91:390–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liew EL, Araki M, Hironaka Y, Mori S, Tan
TZ, Morishita S, Edahiro Y, Ohsaka A and Komatsu N: Identification
of AIM2 as a downstream target of JAK2V617F. Exp Hematol Oncol.
5:22016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mahjoub S, Baccouche H, Sahnoun M, Kaabi
H, Manai Z, Slama H and Ben Romdhane N: The JAK2 mutation in
myeloproliferative disorders: A predictive factor of thrombosis.
Tunis Med. 93:474–477. 2015.(In French). PubMed/NCBI
|
|
5
|
Okabe M, Yamaguchi H, Usuki K, Kobayashi
Y, Kawata E, Kuroda J, Kimura S, Tajika K, Gomi S, Arima N, et al:
Clinical features of Japanese polycythemia vera and essential
thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del,
and MPLW515L/K mutations. Leuk Res. 40:68–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marty C, Pecquet C, Nivarthi H, Elkhoury
M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R,
Constantinescu SN, et al: Calreticulin mutants in mice induce an
MPL-dependent thrombocytosis with frequent progression to
myelofibrosis. Blood. 127:1317–1324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tefferi A, Thiele J and Vardiman JW: The
2008 World Health Organization classification system for
myeloproliferative neoplasms: Order out of chaos. Cancer.
115:3842–3847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Čokić VP, Mitrović-Ajtić O, Beleslin-Čokić
BB, Marković D, Buač M, Diklić M, Kraguljac-Kurtović N, Damjanović
S, Milenković P, Gotić M, et al: Proinflammatory cytokine IL-6 and
JAK-STAT signaling pathway in myeloproliferative neoplasms.
Mediators Inflamm. 2015:4530202015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cabagnols X, Favale F, Pasquier F,
Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin
N, Chachoua I, et al: Presence of atypical thrombopoietin receptor
(MPL) mutations in triple-negative essential thrombocythemia
patients. Blood. 127:333–342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feenstra JD Milosevic, Nivarthi H,
Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B,
Pietra D, Gisslinger B, et al: Whole-exome sequencing identifies
novel MPL and JAK2 mutations in triple-negative myeloproliferative
neoplasms. Blood. 127:325–332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Verger E, Cassinat B, Chauveau A, Dosquet
C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N,
Carillo S, et al: Clinical and molecular response to interferon-α
therapy in essential thrombocythemia patients with CALR mutations.
Blood. 126:2585–2591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klampfl T, Gisslinger H, Harutyunyan AS,
Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B,
Pietra D, et al: Somatic mutations of calreticulin in
myeloproliferative neoplasms. N Engl J Med. 369:2379–2390. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nangalia J, Massie CE, Baxter EJ, Nice FL,
Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al:
Somatic CALR mutations in myeloproliferative neoplasms with
nonmutated JAK2. N Engl J Med. 369:2391–2405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim SY, Im K, Park SN, Kwon J, Kim JA and
Lee DS: CALR, JAK2, and MPL mutation profiles in patients with four
different subtypes of myeloproliferative neoplasms: primary
myelofibrosis, essential thrombocythemia, polycythemia vera, and
myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol.
143:635–644. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rumi E, Pietra D, Ferretti V, Klampfl T,
Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC,
et al: Associazione Italiana per la Ricerca sul Cancro Gruppo
Italiano Malattie Mieloproliferative Investigators: JAK2 or CALR
mutation status defines subtypes of essential thrombocythemia with
substantially different clinical course and outcomes. Blood.
123:1544–1551. 2014. View Article : Google Scholar : PubMed/NCBI
|
